Stifel Starts Sutro Biopharma at Buy With $48 Target on ADC Platform Potential
Stifel highlights ADC platform potential, dual-payload pipeline strength, near-term catalysts, and cash runway through 2028.
/ 1648 items
#XY↓
MIRM Shares Slide on Volixibat Regulatory Delay Despite Robust Q2 Results
Mirum reported robust Q2 2026 net sales of $176.2 million and hiked guidance, yet MIRM stock fell sharply after the FDA asked for an additional Phase 3 study for its PSC drug volixibat.
Insmed Shares Surge ~30% on Explosive BRINSUPRI Launch and Massive Guidance Raise
Insmed delivered a standout Q2 with $425.5M revenue driven by $309M BRINSUPRI sales. Company raised 2026 guidance and long-term peak sales to $14B+.
Black Diamond Therapeutics Shares Jump on Positive Silevertinib Phase 2 Data and Strong Cash Runway
Black Diamond Therapeutics reported Q2 results with robust silevertinib responses, no new brain mets, and cash expected to last into the second half of 2028.
Tarsus to Acquire Alkeus in Up to $800 Million Deal for Rare Eye Disease Drug
Tarsus to acquire Alkeus for up to $800M, adding late-stage oral therapy for Stargardt disease – a rare eye disorder with no approved treatments.
FDA Approves ORZEYFUL: First Medicine to Treat the Root Cause of Narcolepsy Type 1
Twice-daily pill improves wakefulness and reduces symptoms.